Zacks Investment Research
06 Aug 2026, 14:51 UTC · 1h ago
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
06 Aug 2026, 14:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Collegium Pharmaceutical (COLL) reported quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68. — A significant earnings beat (14.29%) typically drives short-term positive price action.
+0.40Collegium Pharmaceutical reported quarterly revenues of $199.88 million, surpassing the Zacks Consensus Estimate by 1.20%. — Revenue growth and a beat of estimates support the company's fundamental strength, though the beat margin is slim.
+0.20Collegium Pharmaceutical shares have declined approximately 22.8% year-to-date, underperforming the S&P 500's 12.8% gain. — Strong negative price momentum suggests lingering investor skepticism despite the current earnings beat.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company beat both quarterly earnings and revenue estimates, showing positive growth over the previous year.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
55m ago
